1
|
Ostrom QT, Cioffi G, Gittleman H, Patil N,
Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: primary brain and other central nervous system tumors
diagnosed in the United States in 2012–2016. Neuro Oncol. 21 (Suppl
5):v1–v100. 2019. View Article : Google Scholar : PubMed/NCBI
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
3
|
Laperriere N, Zuraw L and Cairncross G;
Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology
Disease Site Group, : Radiotherapy for newly diagnosed malignant
glioma in adults: A systematic review. Radiother Oncol. 64:259–273.
2002. View Article : Google Scholar : PubMed/NCBI
|
4
|
Sueoka H, Hirano T, Uda Y, Iimuro Y,
Yamanaka J and Fujimoto J: Blockage of CXCR2 suppresses tumor
growth of intrahepatic cholangiocellular carcinoma. Surgery.
155:640–649. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Marenco-Hillembrand L, Wijesekera O,
Suarez-Meade P, Mampre D, Jackson C, Peterson J, Trifiletti D,
Hammack J, Ortiz K, Lesser E, et al: Trends in glioblastoma:
Outcomes over time and type of intervention: A systematic evidence
based analysis. J Neurooncol. 147:297–307. 2020. View Article : Google Scholar : PubMed/NCBI
|
6
|
Urbantat RM, Vajkoczy P and Brandenburg S:
Advances in chemokine signaling pathways as therapeutic targets in
glioblastoma. Cancers (Basel). 13:29832021. View Article : Google Scholar : PubMed/NCBI
|
7
|
Shibuya M: Vascular endothelial growth
factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A
crucial target for anti- and pro-angiogenic therapies. Genes
Cancer. 2:1097–1105. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Stupp R, Taillibert S, Kanner A, Read W,
Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K,
et al: Effect of tumor-treating fields plus maintenance
temozolomide vs maintenance temozolomide alone on survival in
patients with glioblastoma: A randomized clinical trial. JAMA.
318:2306–2316. 2017. View Article : Google Scholar : PubMed/NCBI
|
9
|
Huang B, Li X, Li Y, Zhang J, Zong Z and
Zhang H: Current immunotherapies for glioblastoma multiforme. Front
Immunol. 11:6039112021. View Article : Google Scholar : PubMed/NCBI
|
10
|
Sampson JH, Maus MV and June CH:
Immunotherapy for brain tumors. J Clin Oncol. 35:2450–2456. 2017.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Acker G, Zollfrank J, Jelgersma C,
Nieminen-Kelhä M, Kremenetskaia I, Mueller S, Ghori A, Vajkoczy P
and Brandenburg S: The CXCR2/CXCL2 signalling pathway-an
alternative therapeutic approach in high-grade glioma. Eur J
Cancer. 126:106–115. 2020. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ahir BK, Engelhard HH and Lakka SS: Tumor
development and angiogenesis in adult brain tumor: Glioblastoma.
Mol Neurobiol. 57:2461–2478. 2020. View Article : Google Scholar : PubMed/NCBI
|
13
|
Takano S, Yamashita T and Ohneda O:
Molecular therapeutic targets for glioma angiogenesis. J Oncol.
2010:3519082010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Szulzewsky F, Pelz A, Feng X, Synowitz M,
Markovic D, Langmann T, Holtman IR, Wang X, Eggen BJ, Boddeke HW,
et al: Glioma-associated microglia/macrophages display an
expression profile different from M1 and M2 polarization and highly
express Gpnmb and Spp1. PLoS One. 10:e01166442015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Hambardzumyan D, Gutmann DH and Kettenmann
H: The role of microglia and macrophages in glioma maintenance and
progression. Nat Neurosci. 19:20–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
16
|
Brandenburg S, Blank A, Bungert AD and
Vajkoczy P: Distinction of microglia and macrophages in
glioblastoma: Close relatives, different tasks? Int J Mol Sci.
22:1942020. View Article : Google Scholar : PubMed/NCBI
|
17
|
Blank A, Kremenetskaia I, Urbantat RM,
Acker G, Turkowski K, Radke J, Schneider UC, Vajkoczy P and
Brandenburg S: Microglia/macrophages express alternative
proangiogenic factors depending on granulocyte content in human
glioblastoma. J Pathol. 253:160–173. 2021. View Article : Google Scholar : PubMed/NCBI
|
18
|
Urbantat RM, Blank A, Kremenetskaia I,
Vajkoczy P, Acker G and Brandenburg S: The CXCL2/IL8/CXCR2 pathway
is relevant for brain tumor malignancy and endothelial cell
function. Int J Mol Sci. 22:26342021. View Article : Google Scholar : PubMed/NCBI
|
19
|
Urbantat RM, Jelgersma C, Brandenburg S,
Nieminen-Kelhä M, Kremenetskaia I, Zollfrank J, Mueller S, Rubarth
K, Koch A, Vajkoczy P and Acker G: Tumor-associated
microglia/macrophages as a predictor for survival in glioblastoma
and temozolomide-induced changes in CXCR2 signaling with new
resistance overcoming strategy by combination therapy. Int J Mol
Sci. 22:111802021. View Article : Google Scholar : PubMed/NCBI
|
20
|
Brandenburg S, Turkowski K, Mueller A,
Radev YT, Seidlitz S and Vajkoczy P: Myeloid cells expressing high
level of CD45 are associated with a distinct activated phenotype in
glioma. Immunol Res. 65:757–768. 2017. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
22
|
Chaudhry IH, O'Donovan DG, Brenchley PE,
Reid H and Roberts IS: Vascular endothelial growth factor
expression correlates with tumour grade and vascularity in gliomas.
Histopathology. 39:409–415. 2001. View Article : Google Scholar : PubMed/NCBI
|
23
|
Norden AD, Drappatz J and Wen PY:
Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol.
20:652–661. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Angara K, Borin TF, Rashid MH, Lebedyeva
I, Ara R, Lin PC, Iskander A, Bollag RJ, Achyut BR and Arbab AS:
CXCR2-expressing tumor cells drive vascular mimicry in
antiangiogenic therapy-resistant glioblastoma. Neoplasia.
20:1070–1082. 2018. View Article : Google Scholar : PubMed/NCBI
|
25
|
Murdoch C, Monk PN and Finn A: Cxc
chemokine receptor expression on human endothelial cells. Cytokine.
11:704–712. 1999. View Article : Google Scholar : PubMed/NCBI
|
26
|
Addison CL, Daniel TO, Burdick MD, Liu H,
Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A and Strieter RM:
The CXC chemokine receptor 2, CXCR2, is the putative receptor for
ELR+ CXC chemokine-induced angiogenic activity. J Immunol.
165:5269–5277. 2000. View Article : Google Scholar : PubMed/NCBI
|
27
|
Brat DJ, Bellail AC and Van Meir EG: The
role of interleukin-8 and its receptors in gliomagenesis and
tumoral angiogenesis. Neuro Oncol. 7:122–133. 2005. View Article : Google Scholar : PubMed/NCBI
|
28
|
Hillyer P, Mordelet E, Flynn G and Male D:
Chemokines, chemokine receptors and adhesion molecules on different
human endothelia: Discriminating the tissue-specific functions that
affect leucocyte migration. Clin Exp Immunol. 134:431–441. 2003.
View Article : Google Scholar : PubMed/NCBI
|
29
|
de Vasconcellos JF, Laranjeira AB, Leal
PC, Bhasin MK, Zenatti PP, Nunes RJ, Yunes RA, Nowill AE, Libermann
TA, Zerbini LF and Yunes JA: SB225002 induces cell death and cell
cycle arrest in acute lymphoblastic leukemia cells through the
activation of GLIPR1. PLoS One. 10:e01347832015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Li A, Dubey S, Varney ML, Dave BJ and
Singh RK: IL-8 directly enhanced endothelial cell survival,
proliferation, and matrix metalloproteinases production and
regulated angiogenesis. J Immunol. 170:3369–3376. 2003. View Article : Google Scholar : PubMed/NCBI
|
31
|
Goda AE, Koyama M, Sowa Y, Elokely KM,
Yoshida T, Kim BY and Sakai T: Molecular mechanisms of the
antitumor activity of SB225002: A novel microtubule inhibitor.
Biochem Pharmacol. 85:1741–1752. 2013. View Article : Google Scholar : PubMed/NCBI
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Gale NW and Yancopoulos GD: Growth factors
acting via endothelial cell-specific receptor tyrosine kinases:
VEGFs, angiopoietins, and ephrins in vascular development. Genes
Dev. 13:1055–1066. 1999. View Article : Google Scholar : PubMed/NCBI
|
34
|
Waltenberger J, Claesson-Welsh L, Siegbahn
A, Shibuya M and Heldin CH: Different signal transduction
properties of KDR and Flt1, two receptors for vascular endothelial
growth factor. J Biol Chem. 269:26988–26995. 1994. View Article : Google Scholar : PubMed/NCBI
|
35
|
Imoukhuede PI and Popel AS: Quantification
and cell-to-cell variation of vascular endothelial growth factor
receptors. Exp Cell Res. 317:955–965. 2011. View Article : Google Scholar : PubMed/NCBI
|
36
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
37
|
Ferrara N: The role of VEGF in the
regulation of physiological and pathological angiogenesis. EXS.
209–231. 2005.PubMed/NCBI
|
38
|
Nör JE, Christensen J, Liu J, Peters M,
Mooney DJ, Strieter RM and Polverini PJ: Up-regulation of Bcl-2 in
microvascular endothelial cells enhances intratumoral angiogenesis
and accelerates tumor growth. Cancer Res. 61:2183–2188.
2001.PubMed/NCBI
|
39
|
Karl E, Zhang Z, Dong Z, Neiva KG, Soengas
MS, Koch AE, Polverini PJ, Núñez G and Nör JE: Unidirectional
crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic
phenotype of endothelial cells. Cell Death Differ. 14:1657–1666.
2007. View Article : Google Scholar : PubMed/NCBI
|
40
|
Strieter RM, Burdick MD, Mestas J,
Gomperts B, Keane MP and Belperio JA: Cancer CXC chemokine networks
and tumour angiogenesis. Eur J Cancer. 42:768–778. 2006. View Article : Google Scholar : PubMed/NCBI
|
41
|
Ghosh D, Nandi S and Bhattacharjee S:
Combination therapy to checkmate glioblastoma: Clinical challenges
and advances. Clin Transl Med. 7:332018. View Article : Google Scholar : PubMed/NCBI
|
42
|
Wang B, Hendricks DT, Wamunyokoli F and
Parker MI: A growth-related oncogene/CXC chemokine receptor 2
autocrine loop contributes to cellular proliferation in esophageal
cancer. Cancer Res. 66:3071–3077. 2006. View Article : Google Scholar : PubMed/NCBI
|
43
|
Matsuo Y, Campbell PM, Brekken RA, Sung B,
Ouellette MM, Fleming JB, Aggarwal BB, Der CJ and Guha S: K-Ras
promotes angiogenesis mediated by immortalized human pancreatic
epithelial cells through mitogen-activated protein kinase signaling
pathways. Mol Cancer Res. 7:799–808. 2009. View Article : Google Scholar : PubMed/NCBI
|
44
|
Yu M, Berk R and Kosir MA: CXCL7-mediated
stimulation of lymphangiogenic factors VEGF-C, VEGF-D in human
breast cancer cells. J Oncol. 2010:9394072010. View Article : Google Scholar : PubMed/NCBI
|
45
|
Saintigny P, Massarelli E, Lin S, Ahn YH,
Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, et al: CXCR2
expression in tumor cells is a poor prognostic factor and promotes
invasion and metastasis in lung adenocarcinoma. Cancer Res.
73:571–582. 2013. View Article : Google Scholar : PubMed/NCBI
|
46
|
Hasan T, Caragher SP, Shireman JM, Park
CH, Atashi F, Baisiwala S, Lee G, Guo D, Wang JY, Dey M, et al:
Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity
and enhances tumorigenicity in glioblastoma. Cell Death Dis.
10:2922019. View Article : Google Scholar : PubMed/NCBI
|
47
|
Erin N, Nizam E, Tanrıöver G and Köksoy S:
Autocrine control of MIP-2 secretion from metastatic breast cancer
cells is mediated by CXCR2: A mechanism for possible resistance to
CXCR2 antagonists. Breast Cancer Res Treat. 150:57–69. 2015.
View Article : Google Scholar : PubMed/NCBI
|
48
|
Koch AE, Polverini PJ, Kunkel SL, Harlow
LA, DiPietro LA, Elner VM, Elner SG and Strieter RM: Interleukin-8
as a macrophage-derived mediator of angiogenesis. Science.
258:1798–1801. 1992. View Article : Google Scholar : PubMed/NCBI
|
49
|
Cheng Z, Teo G, Krueger S, Rock TM, Koh
HW, Choi H and Vogel C: Differential dynamics of the mammalian mRNA
and protein expression response to misfolding stress. Mol Syst
Biol. 12:8552016. View Article : Google Scholar : PubMed/NCBI
|
50
|
Vogel C and Marcotte EM: Insights into the
regulation of protein abundance from proteomic and transcriptomic
analyses. Nat Rev Genet. 13:227–232. 2012. View Article : Google Scholar : PubMed/NCBI
|
51
|
Buccitelli C and Selbach M: mRNAs,
proteins and the emerging principles of gene expression control.
Nat Rev Genet. 21:630–644. 2020. View Article : Google Scholar : PubMed/NCBI
|
52
|
Sharma I, Singh A, Siraj F and Saxena S:
IL-8/CXCR1/2 signalling promotes tumor cell proliferation, invasion
and vascular mimicry in glioblastoma. J Biomed Sci. 25:622018.
View Article : Google Scholar : PubMed/NCBI
|
53
|
Baisiwala S, Auffinger B, Caragher SP,
Shireman JM, Ahsan R, Lee G, Hasan T, Park C, Saathoff MR,
Christensen AC and Ahmed AU: Chemotherapeutic stress induces
transdifferentiation of glioblastoma cells to endothelial cells and
promotes vascular mimicry. Stem Cells Int. 2019:61074562019.
View Article : Google Scholar : PubMed/NCBI
|
54
|
Lauko A, Lo A, Ahluwalia MS and Lathia JD:
Cancer cell heterogeneity & plasticity in glioblastoma and
brain tumors. Semin Cancer Biol. 82:162–175. 2022. View Article : Google Scholar : PubMed/NCBI
|
55
|
Perrin SL, Samuel MS, Koszyca B, Brown MP,
Ebert LM, Oksdath M and Gomez GA: Glioblastoma heterogeneity and
the tumour microenvironment: Implications for preclinical research
and development of new treatments. Biochem Soc Trans. 47:625–638.
2019. View Article : Google Scholar : PubMed/NCBI
|
56
|
Qazi MA, Vora P, Venugopal C, Sidhu SS,
Moffat J, Swanton C and Singh SK: Intratumoral heterogeneity:
Pathways to treatment resistance and relapse in human glioblastoma.
Ann Oncol. 28:1448–1456. 2017. View Article : Google Scholar : PubMed/NCBI
|
57
|
Thomas RP, Nagpal S, Iv M, Soltys SG,
Bertrand S, Pelpola JS, Ball R, Yang J, Sundaram V, Lavezo J, et
al: Macrophage exclusion after radiation therapy (MERT): A first in
human phase I/II trial using a CXCR4 inhibitor in glioblastoma.
Clin Cancer Res. 25:6948–6957. 2019. View Article : Google Scholar : PubMed/NCBI
|